COVID-19 VACCINE INFORMATION
Learn more about the vaccine and how it can help protect you and your family from COVID-19.
Health Care Provider Education Documents
General Immunization Documents for Patients
General Immunization Documents for Immunizers and Vaccine Clinics
Consent for COVID-19 Vaccination Documents
Ministry of Health Statement
FREQUENTLY ASKED QUESTIONS:
Both Pfizer and NACI guidelines state that if a client had a vaccine (including a vaccine for influenza) within 14 days of the scheduled date of the BioNTech COVID-19 vaccine, then the BioNTech COVID-19 vaccine should be delayed until the 14-day period has passed.
If a client has had the BioNTech COVID-19 vaccine series, another vaccine should not be administered within 28 days of the last dose (except in the case of post-exposure prophylaxis) due to elicitation of inflammatory cytokine response.
According to NACI guidelines, individuals on long-term anticoagulation are not at a significant risk for bleed and can receive the vaccine.
|Yes. You still receive your second dose unless you yourself are positive. See next question and answer if you yourself become positive between doses.
|You should wait until you are clear of symptoms and Public Health has cleared you from self-isolation before receiving the second dose.
NACI guidelines state:
As a precautionary measure and in light of the need to be able to monitor for COVID-19 vaccine adverse events without potential confounding from symptoms of COVID-19 or other co-existing illnesses, it would be prudent to wait until all symptoms of an acute illness are completely resolved before vaccinating with an authorized COVID-19 vaccine
NACI guidelines state further:
If the administration of the second dose of a COVID-19 vaccine is delayed, the second dose should be provided as soon as possible. Currently, no data on a maximum interval between doses or on medium- or long-term efficacy of COVID-19 vaccines are available. Therefore, every effort should be made to vaccinate with the second dose according to the recommended schedule.
In general, regardless of the time between doses, interruption of a vaccine series does not require restarting the series as delays between doses do not result in a reduction in final antibody concentrations for most multi-dose products. However, the follow-up time in COVID-19 vaccine clinical trials is short and maximum protection may not be attained until the complete vaccine series has been administered.